| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 13.8908 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 13.8908. The average price that 007390.KQ shares were previous bought at was KRW 21.2531. The current market price is -34.6% lower than average price they were purchased at. The value of the holding in 007390.KQ has fallen by KRW 10,725 (USD $7) compared to the previous valuation of NatureCell Co.,Ltd. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 30.7436 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 30.7436. The average price that 039200.KQ shares were previous bought at was KRW 21.4717. The current market price is 43.2% higher than average price they were purchased at. The value of the holding in 039200.KQ has fallen by KRW 25,616 (USD $18) compared to the previous valuation of Oscotec Inc. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 145.717 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 145.717. The average price that 068270.KS shares were previous bought at was KRW 122.995. The current market price is 18.5% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 393,308 (USD $270) compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.6485 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.6485. The average price that 096530.KQ shares were previous bought at was KRW 17.3894. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 8,290 (USD $6) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.96028 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.96028. The average price that 13.HK shares were previous bought at was HKD 2.98923. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in 13.HK has fallen by HKD 13,636 (USD $1,750) compared to the previous valuation of HUTCHMED (CHINA) LTD |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 3.92005 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.18859 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.18859. The average price that 1877.HK shares were previous bought at was HKD 2.63373. The current market price is 21.1% higher than average price they were purchased at. The value of the holding in 1877.HK has fallen by HKD 7,354 (USD $944) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 1265.83 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 1265.83. The average price that 207940.KS shares were previous bought at was KRW 823.659. The current market price is 53.7% higher than average price they were purchased at. The value of the holding in 207940.KS has fallen by KRW 284,275 (USD $195) compared to the previous valuation of SAMSUNG BIOLOGICS LTD |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.54821 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.54821. The average price that 2162.HK shares were previous bought at was HKD 5.45166. The current market price is 38.5% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 8,288 (USD $1,063) compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 3.43742 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 3.43742. The average price that 2252.HK shares were previous bought at was HKD 3.17344. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 90,879 (USD $11,660) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 86.8855 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 86.8855. The average price that 237690.KQ shares were previous bought at was KRW 61.4105. The current market price is 41.5% higher than average price they were purchased at. The value of the holding in 237690.KQ has fallen by KRW 56,059 (USD $39) compared to the previous valuation of ST Pharm Co.,Ltd. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 137.205 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 137.205. The average price that 298380.KQ shares were previous bought at was KRW 105.452. The current market price is 30.1% higher than average price they were purchased at. The value of the holding in 298380.KQ has fallen by KRW 133,542 (USD $92) compared to the previous valuation of ABL Bio Inc. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 32.3097 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 32.3097. The average price that 302440.KS shares were previous bought at was KRW 35.8723. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 20,292 (USD $14) compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 83.7532 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 83.7532. The average price that 326030.KS shares were previous bought at was KRW 79.0164. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in 326030.KS has fallen by KRW 69,790 (USD $48) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 26.2154 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 26.2154. The average price that 328130.KQ shares were previous bought at was KRW 35.7727. The current market price is -26.7% lower than average price they were purchased at. The value of the holding in 328130.KQ has fallen by KRW 20,579 (USD $14) compared to the previous valuation of Lunit Inc. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.53016 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.53016. The average price that 3933.HK shares were previous bought at was HKD 1.65449. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in 3933.HK has fallen by HKD 5,043 (USD $647) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 30.1795 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 30.1795. The average price that 4523.T shares were previous bought at was JPY 28.6697. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 5,423 (USD $34) compared to the previous valuation of Eisai Co., Ltd. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.593 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.593. The average price that 4549.T shares were previous bought at was JPY 13.7881. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 228 (USD $1) compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.9841 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.9841. The average price that 4587.T shares were previous bought at was JPY 11.0411. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 708 (USD $4) compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 15.1942 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 15.1942. The average price that 4887.T shares were previous bought at was JPY 13.6093. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in 4887.T has fallen by JPY 917 (USD $6) compared to the previous valuation of Sawai Group Holdings Co., Ltd. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.19134 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.19134. The average price that 4974.T shares were previous bought at was JPY 5.64514. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in 4974.T has fallen by JPY 153 (USD $1) compared to the previous valuation of Takara Bio Inc. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.98386 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.98386. The average price that 6869.T shares were previous bought at was JPY 14.294. The current market price is -30.2% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 3,218 (USD $20) compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 32.5979 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 32.5979. The average price that 6951.T shares were previous bought at was JPY 33.0116. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in 6951.T has fallen by JPY 1,029 (USD $7) compared to the previous valuation of JEOL Ltd. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 10.1421 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 10.1421. The average price that 7575.T shares were previous bought at was JPY 10.1731. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in 7575.T has fallen by JPY 359 (USD $2) compared to the previous valuation of Japan Lifeline Co., Ltd. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.2546 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.2546. The average price that 7701.T shares were previous bought at was JPY 26.5384. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 4,972 (USD $31) compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.6952 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.6952. The average price that 7747.T shares were previous bought at was JPY 17.2251. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in 7747.T has fallen by JPY 2,845 (USD $18) compared to the previous valuation of Asahi Intecc Co., Ltd. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 11.9027 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 11.9027. The average price that 9995.HK shares were previous bought at was HKD 9.92476. The current market price is 19.9% higher than average price they were purchased at. The value of the holding in 9995.HK has fallen by HKD 48,867 (USD $6,270) compared to the previous valuation of REMEGEN LTD H |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 147.99 | USD 0 | The current share valuation price of A based on adjusted close was USD 147.99. The average price that A shares were previous bought at was USD 124.128. The current market price is 19.2% higher than average price they were purchased at. The value of the holding in A has fallen by USD 66,287 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 220.04 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 220.04. The average price that ABBV shares were previous bought at was USD 207.34. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 3,181 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 4.52 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 4.52. The average price that ABCL shares were previous bought at was USD 3.64146. The current market price is 24.1% higher than average price they were purchased at. The value of the holding in ABCL has increased by USD 41,920 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 124.64 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 124.64. The average price that ABT shares were previous bought at was USD 124.851. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in ABT has fallen by USD 143,843 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 26.59 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 26.59. The average price that ACAD shares were previous bought at was USD 20.8983. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 28,725 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 64.87 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 64.87. The average price that ACLX shares were previous bought at was USD 64.8573. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in ACLX has fallen by USD 71,552 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 18.26 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 18.26. The average price that ADPT shares were previous bought at was USD 7.31543. The current market price is 149.6% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 461,208 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.62 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.62. The average price that ALKS shares were previous bought at was USD 30.114. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 8,128 compared to the previous valuation of Alkermes Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 325.54 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 325.54. The average price that AMGN shares were previous bought at was USD 301.323. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 28,766 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.39 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.39. The average price that AMLX shares were previous bought at was USD 12.8622. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in AMLX has increased by USD 16,116 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 49.03 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 49.03. The average price that ANAB shares were previous bought at was USD 24.8769. The current market price is 97.1% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 113,766 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 7.52999 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 7.52999. The average price that ARCT shares were previous bought at was USD 11.4139. The current market price is -34.0% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 19,742 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.15 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.15. The average price that ARVN shares were previous bought at was USD 11.4152. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 6,832 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 29.21 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 29.21. The average price that ASTH shares were previous bought at was USD 26.6276. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in ASTH has increased by USD 38,172 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 37.64 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 37.64. The average price that ATRC shares were previous bought at was USD 34.2643. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in ATRC has fallen by USD 228,956 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 15.28 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 15.28. The average price that AUPH shares were previous bought at was USD 12.3962. The current market price is 23.3% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 20,918 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 31.55 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 31.55. The average price that AXGN shares were previous bought at was USD 19.4564. The current market price is 62.2% higher than average price they were purchased at. The value of the holding in AXGN has fallen by USD 104,506 compared to the previous valuation of Axogen Inc |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 176.82 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 176.82. The average price that AXSM shares were previous bought at was USD 127.917. The current market price is 38.2% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 350,535 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| BANB.SW - | HOLD | 0 @ CHF 80.2713 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 80.2713. The average price that BANB.SW shares were previous bought at was CHF 68.9205. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 85,574 (USD $106,764) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 31.0416 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 31.0416. The average price that BAVA.CO shares were previous bought at was DKK 25.9676. The current market price is 19.5% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 9,802 (USD $1,525) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.09 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.09. The average price that BCRX shares were previous bought at was USD 7.7571. The current market price is -8.6% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 80,878 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 33.69 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 33.69. The average price that BEAM shares were previous bought at was USD 19.0014. The current market price is 77.3% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 759,991 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 185.63 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 185.63. The average price that BIIB shares were previous bought at was USD 132.569. The current market price is 40.0% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 221,385 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 127.801 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 127.801. The average price that BIM.PA shares were previous bought at was EUR 123.512. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 216,737 (USD $251,929) compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 323 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 323. The average price that BIO shares were previous bought at was USD 293.687. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 21,271 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 323 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 323. The average price that BIO shares were previous bought at was USD 293.687. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 21,271 compared to the previous valuation of Biotest Aktiengesellschaft |
| BIOA-B.ST - | HOLD | 0 @ SEK 35.77 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 35.77. The average price that BIOA-B.ST shares were previous bought at was SEK 30.6339. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has fallen by SEK 19,305 (USD $2,095) compared to the previous valuation of |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 24.04 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 24.04. The average price that BLFS shares were previous bought at was USD 25.4822. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 46,631 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 55.77 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 55.77. The average price that BMY shares were previous bought at was USD 53.6374. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in BMY has fallen by USD 27,148 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 95.72 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 95.72. The average price that BSX shares were previous bought at was USD 97.443. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 291,330 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 95.72 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 95.72. The average price that BSX shares were previous bought at was USD 97.443. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 291,330 compared to the previous valuation of MULSTRXSSXIMETFP |
| CDNA - Caredx Inc | HOLD | 0 @ USD 20.57 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 20.57. The average price that CDNA shares were previous bought at was USD 19.1809. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in CDNA has increased by USD 214,711 compared to the previous valuation of Caredx Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 9.39 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 9.39. The average price that CERT shares were previous bought at was USD 10.3075. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in CERT has increased by USD 8,496 compared to the previous valuation of Certara Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 53.72 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 53.72. The average price that CGON shares were previous bought at was USD 41.6894. The current market price is 28.9% higher than average price they were purchased at. The value of the holding in CGON has fallen by USD 36,096 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CHEMM.CO - | HOLD | 0 @ DKK 112.488 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 112.488. The average price that CHEMM.CO shares were previous bought at was DKK 81.1711. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 35,033 (USD $5,450) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 23.22 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 23.22. The average price that CPRX shares were previous bought at was USD 22.479. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in CPRX has increased by USD 74,804 compared to the previous valuation of Catalyst Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| CRL - Creightons Plc | HOLD | 0 @ USD 218.82 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 218.82. The average price that CRL shares were previous bought at was USD 173.854. The current market price is 25.9% higher than average price they were purchased at. The value of the holding in CRL has fallen by USD 125,830 compared to the previous valuation of Creightons Plc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 70.58 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 70.58. The average price that CRVL shares were previous bought at was USD 110.855. The current market price is -36.3% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 30,238 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.66 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.66. The average price that CSTL shares were previous bought at was USD 22.871. The current market price is 73.4% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 11,224 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.8 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.8. The average price that CTKB shares were previous bought at was USD 5.67707. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in CTKB has increased by USD 55,759 compared to the previous valuation of Cytek Biosciences Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 11.33 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 11.33. The average price that DAWN shares were previous bought at was USD 8.8232. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 221,197 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 239 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 239. The average price that DHR shares were previous bought at was USD 201.944. The current market price is 18.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 46,866 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 239 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 239. The average price that DHR shares were previous bought at was USD 201.944. The current market price is 18.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 46,866 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 85.7926 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 85.7926. The average price that DIA.MI shares were previous bought at was EUR 62.7228. The current market price is 36.8% higher than average price they were purchased at. The value of the holding in DIA.MI has increased by EUR 42,461 (USD $49,355) compared to the previous valuation of DiaSorin SpA however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 15.68 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 15.68. The average price that DVAX shares were previous bought at was USD 13.6965. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 40,244 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 70.98 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 70.98. The average price that DXCM shares were previous bought at was USD 78.2515. The current market price is -9.3% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 636,198 compared to the previous valuation of DexCom Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 11.1304 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 11.1304. The average price that DYVOX.ST shares were previous bought at was SEK 7.53453. The current market price is 47.7% higher than average price they were purchased at. The value of the holding in DYVOX.ST has fallen by SEK 2,807 (USD $305) compared to the previous valuation of |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.58002 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.58002. The average price that EKTA-B.ST shares were previous bought at was SEK 5.73375. The current market price is 14.8% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 29,332 (USD $3,183) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 12.85 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 12.85. The average price that EMBC shares were previous bought at was USD 12.7299. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in EMBC has increased by USD 6,288 compared to the previous valuation of Embecta Corp however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 18.9832 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 18.9832. The average price that EUZ.DE shares were previous bought at was EUR 18.573. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 777 (USD $903) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.15 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.15. The average price that EVH shares were previous bought at was USD 8.8329. The current market price is -53.0% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 2,572 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 7.55124 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 7.55124. The average price that EVT.DE shares were previous bought at was EUR 6.62492. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 42,547 (USD $49,455) compared to the previous valuation of Evotec SE however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 83.01 | USD 0 | The current share valuation price of EW based on adjusted close was USD 83.01. The average price that EW shares were previous bought at was USD 75.446. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 421,576 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 102.23 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 102.23. The average price that EXAS shares were previous bought at was USD 68.5092. The current market price is 49.2% higher than average price they were purchased at. The value of the holding in EXAS has increased by USD 27,748 compared to the previous valuation of EXACT Sciences Corporation however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 44.06 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 44.06. The average price that EXEL shares were previous bought at was USD 39.465. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 6,685 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 18.4 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 18.4. The average price that FTRE shares were previous bought at was USD 11.3862. The current market price is 61.6% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 113,311 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 107.57 | USD 0 | The current share valuation price of GH based on adjusted close was USD 107.57. The average price that GH shares were previous bought at was USD 63.8847. The current market price is 68.4% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 394,847 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 122.6 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 122.6. The average price that GILD shares were previous bought at was USD 109.888. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 205,377 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 32.8031 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 32.8031. The average price that GLPG.AS shares were previous bought at was EUR 29.9957. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in GLPG.AS has fallen by EUR 9,660 (USD $11,229) compared to the previous valuation of Galapagos NV |
| GMAB.CO - | HOLD | 0 @ DKK 338.011 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 338.011. The average price that GMAB.CO shares were previous bought at was DKK 229.757. The current market price is 47.1% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 126,058 (USD $19,612) compared to the previous valuation of |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 25.2935 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 25.2935. The average price that GSK.L shares were previous bought at was GBP 20.1291. The current market price is 25.7% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 10,186 (USD $13,643) compared to the previous valuation of GlaxoSmithKline PLC |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 72.42 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 72.42. The average price that HALO shares were previous bought at was USD 62.5816. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 7,552 compared to the previous valuation of Halozyme Therapeutics Inc |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.88216 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.88216. The average price that HLUN-B.CO shares were previous bought at was DKK 6.2927. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has fallen by DKK 35,096 (USD $5,460) compared to the previous valuation of |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.86 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.86. The average price that HOLX shares were previous bought at was USD 67.0082. The current market price is 11.7% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 2,314 compared to the previous valuation of Hologic Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 38.27 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 38.27. The average price that HRMY shares were previous bought at was USD 33.8042. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 15,569 compared to the previous valuation of Harmony Biosciences Holdings |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 13.15 | USD 0 | The current share valuation price of IART based on adjusted close was USD 13.15. The average price that IART shares were previous bought at was USD 15.729. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in IART has fallen by USD 37,930 compared to the previous valuation of Integra LifeSciences Holdings |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.59 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.59. The average price that IBRX shares were previous bought at was USD 2.78763. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 72,359 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 36.84 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 36.84. The average price that IDYA shares were previous bought at was USD 24.4744. The current market price is 50.5% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 57,895 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 145.55 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 145.55. The average price that ILMN shares were previous bought at was USD 98.0231. The current market price is 48.5% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 767,536 compared to the previous valuation of Illumina Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.4 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.4. The average price that IOVA shares were previous bought at was USD 2.42818. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 16,820 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 151.048 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 151.048. The average price that IPN.PA shares were previous bought at was EUR 125.397. The current market price is 20.5% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 122,268 (USD $142,121) compared to the previous valuation of Ipsen SA however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 240.86 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 240.86. The average price that IQV shares were previous bought at was USD 166.332. The current market price is 44.8% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 146,233 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 572.745 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 572.745. The average price that ISRG shares were previous bought at was USD 543.06. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 384,082 compared to the previous valuation of Intuitive Surgical Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 14.03 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 14.03. The average price that JANX shares were previous bought at was USD 24.4033. The current market price is -42.5% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 9,051 compared to the previous valuation of Janux Therapeutics Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 209.72 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 209.72. The average price that JNJ shares were previous bought at was USD 179.01. The current market price is 17.2% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 513,518 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 41.12 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 41.12. The average price that KNSA shares were previous bought at was USD 40.6381. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 81,665 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.17 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.17. The average price that KURA shares were previous bought at was USD 10.4294. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in KURA has fallen by USD 22,798 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.51 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.51. The average price that LAB shares were previous bought at was USD 1.34282. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in LAB has fallen by USD 12,599 compared to the previous valuation of Standard Biotools Inc |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 206.81 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 206.81. The average price that LGND shares were previous bought at was USD 131.097. The current market price is 57.8% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 3,760 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 62.38 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 62.38. The average price that LIVN shares were previous bought at was USD 52.261. The current market price is 19.4% higher than average price they were purchased at. The value of the holding in LIVN has fallen by USD 135,679 compared to the previous valuation of LivaNova PLC |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 67.48 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 67.48. The average price that LNTH shares were previous bought at was USD 75.9324. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 6,740 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 710.759 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 710.759. The average price that LONN.SW shares were previous bought at was CHF 648.057. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 424,407 (USD $529,499) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 96.95 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 96.95. The average price that MDT shares were previous bought at was USD 91.6554. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 99,391 compared to the previous valuation of Medtronic PLC |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 599.21 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 599.21. The average price that MEDP shares were previous bought at was USD 414.159. The current market price is 44.7% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 123,892 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 96.59 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 96.59. The average price that MMS shares were previous bought at was USD 78.1639. The current market price is 23.6% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 31,847 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 109.19 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 109.19. The average price that MRK shares were previous bought at was USD 81.94. The current market price is 33.3% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 248,287 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 109.19 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 109.19. The average price that MRK shares were previous bought at was USD 81.94. The current market price is 33.3% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 248,287 compared to the previous valuation of Merck & Company Inc |
| MRNA - Moderna Inc | HOLD | 0 @ USD 33.84 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 33.84. The average price that MRNA shares were previous bought at was USD 26.1314. The current market price is 29.5% higher than average price they were purchased at. The value of the holding in MRNA has fallen by USD 218,006 compared to the previous valuation of Moderna Inc |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.94 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.94. The average price that MRVI shares were previous bought at was USD 3.01522. The current market price is 30.7% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 1,582 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.57 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.57. The average price that MYGN shares were previous bought at was USD 8.41174. The current market price is -21.9% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 1,103 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 132.66 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 132.66. The average price that NBIX shares were previous bought at was USD 129.085. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 378,126 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 9.37 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 9.37. The average price that NEOG shares were previous bought at was USD 9.66202. The current market price is -3.0% lower than average price they were purchased at. The value of the holding in NEOG has fallen by USD 65,241 compared to the previous valuation of Neogen Corporation |
| NEU.AX - | HOLD | 0 @ AUD 12.983 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.983. The average price that NEU.AX shares were previous bought at was AUD 9.16792. The current market price is 41.6% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 22,524 (USD $15,059) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 143.006 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 143.006. The average price that NOVN.SW shares were previous bought at was CHF 118.826. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 83,897 (USD $104,672) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 235.45 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 235.45. The average price that NTRA shares were previous bought at was USD 186.819. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 104,004 compared to the previous valuation of Natera Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 6.46 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 6.46. The average price that NUVB shares were previous bought at was USD 8.10074. The current market price is -20.3% lower than average price they were purchased at. The value of the holding in NUVB has fallen by USD 481,251 compared to the previous valuation of Nuvation Bio Inc |
| NVAX - Novavax Inc | HOLD | 0 @ USD 7.75 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.75. The average price that NVAX shares were previous bought at was USD 6.56044. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 87,870 compared to the previous valuation of Novavax Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 7.75 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.75. The average price that NVAX shares were previous bought at was USD 6.56044. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 87,870 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 14.18 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 14.18. The average price that NVCR shares were previous bought at was USD 16.14. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 21,675 compared to the previous valuation of Novocure Ltd |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 2.07523 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 2.07523. The average price that ONT.L shares were previous bought at was GBP 1.75834. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 129,304 (USD $173,193) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.01 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.01. The average price that PACB shares were previous bought at was USD 1.41864. The current market price is 41.7% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 25,627 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.27 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.27. The average price that PFE shares were previous bought at was USD 24.413. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 130,263 compared to the previous valuation of Pfizer Inc |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.85744 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.85744. The average price that PHARM.AS shares were previous bought at was EUR 0.965607. The current market price is 92.4% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 16,121 (USD $18,739) compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 94.6826 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 94.6826. The average price that PHM.MC shares were previous bought at was EUR 87.6534. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 33,316 (USD $38,726) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 143.378 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 143.378. The average price that PME.AX shares were previous bought at was AUD 162.274. The current market price is -11.6% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 202,236 (USD $135,211) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 278.55 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 278.55. The average price that PODD shares were previous bought at was USD 284.199. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 529,315 compared to the previous valuation of Insulet Corporation |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 275.74 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 275.74. The average price that PRAX shares were previous bought at was USD 217.338. The current market price is 26.9% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 319,098 compared to the previous valuation of Praxis Precision Medicines Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 77.59 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 77.59. The average price that PTCT shares were previous bought at was USD 60.4688. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 5,829 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 33.36 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 33.36. The average price that QDEL shares were previous bought at was USD 29.5396. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in QDEL has fallen by USD 23,870 compared to the previous valuation of Quidel Corporation |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 21.3 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 21.3. The average price that RCUS shares were previous bought at was USD 10.5136. The current market price is 102.6% higher than average price they were purchased at. The value of the holding in RCUS has increased by USD 26,865 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 168.4 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 168.4. The average price that RGEN shares were previous bought at was USD 149.795. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in RGEN has increased by USD 101,643 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 15.08 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 15.08. The average price that RGNX shares were previous bought at was USD 9.08823. The current market price is 65.9% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 26,379 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 7.8 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 7.8. The average price that RLAY shares were previous bought at was USD 7.13261. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 34,381 compared to the previous valuation of Relay Therapeutics Inc |
| RO.SW - | HOLD | 0 @ CHF 439.671 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 439.671. The average price that RO.SW shares were previous bought at was CHF 374.9. The current market price is 17.3% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 7,674 (USD $9,574) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 430.249 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 430.249. The average price that ROG.SW shares were previous bought at was CHF 341.238. The current market price is 26.1% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 213,703 (USD $266,620) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 103.89 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 103.89. The average price that RVTY shares were previous bought at was USD 99.9844. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in RVTY has fallen by USD 78,022 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.81 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.81. The average price that RXRX shares were previous bought at was USD 5.07682. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 74,773 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 104.89 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 104.89. The average price that RYTM shares were previous bought at was USD 73.5556. The current market price is 42.6% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 275,389 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 18.64 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 18.64. The average price that SDGR shares were previous bought at was USD 20.4142. The current market price is -8.7% lower than average price they were purchased at. The value of the holding in SDGR has increased by USD 18,720 compared to the previous valuation of Schrodinger Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 25.6654 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 25.6654. The average price that SECT-B.ST shares were previous bought at was SEK 27.82. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in SECT-B.ST has fallen by SEK 47,263 (USD $5,128) compared to the previous valuation of |
| SFZN.SW - | HOLD | 0 @ CHF 103.385 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 103.385. The average price that SFZN.SW shares were previous bought at was CHF 123.235. The current market price is -16.1% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 122,595 (USD $152,952) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 18.91 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 18.91. The average price that SLP shares were previous bought at was USD 25.684. The current market price is -26.4% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 12,622 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.14 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.14. The average price that SRPT shares were previous bought at was USD 43.0883. The current market price is -50.9% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 327,658 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 303.966 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 303.966. The average price that SRT3.DE shares were previous bought at was EUR 257.489. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 137,453 (USD $159,771) compared to the previous valuation of Sartorius AG however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 29.42 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 29.42. The average price that STOK shares were previous bought at was USD 13.7915. The current market price is 113.3% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 232,945 compared to the previous valuation of Stoke Therapeutics Inc |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 51.36 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 51.36. The average price that SUPN shares were previous bought at was USD 40.0753. The current market price is 28.2% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 17,317 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 66.56 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 66.56. The average price that TECH shares were previous bought at was USD 59.7202. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in TECH has increased by USD 165,264 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 201.369 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 201.369. The average price that TECN.SW shares were previous bought at was CHF 193.018. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 200,558 (USD $250,220) compared to the previous valuation of however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 27.72 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 27.72. The average price that TGTX shares were previous bought at was USD 32.9266. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in TGTX has fallen by USD 132,833 compared to the previous valuation of TG Therapeutics Inc |
| TMO - Time Out Group plc | HOLD | 0 @ USD 615.45 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 615.45. The average price that TMO shares were previous bought at was USD 428.065. The current market price is 43.8% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 123,991 compared to the previous valuation of Time Out Group plc |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 21.35 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 21.35. The average price that TNDM shares were previous bought at was USD 21.2695. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in TNDM has fallen by USD 29,165 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 38.04 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 38.04. The average price that TWST shares were previous bought at was USD 36.1057. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in TWST has increased by USD 186,228 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 19.8 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 19.8. The average price that TXG shares were previous bought at was USD 13.7856. The current market price is 43.6% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 91,092 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 19.8 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 19.8. The average price that TXG shares were previous bought at was USD 13.7856. The current market price is 43.6% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 91,092 compared to the previous valuation of Terex Corporation |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 294.27 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 294.27. The average price that UCB.BR shares were previous bought at was EUR 221.41. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 187,565 (USD $218,020) compared to the previous valuation of UCB SA |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 43.45 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 43.45. The average price that VCYT shares were previous bought at was USD 36.0106. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 125,896 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.92 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.92. The average price that VIR shares were previous bought at was USD 7.00495. The current market price is -15.5% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 8,627 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.92 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.92. The average price that VIR shares were previous bought at was USD 7.00495. The current market price is -15.5% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 8,627 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.92513 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.92513. The average price that VLA.PA shares were previous bought at was EUR 2.97536. The current market price is 65.5% higher than average price they were purchased at. The value of the holding in VLA.PA has fallen by EUR 4,859 (USD $5,648) compared to the previous valuation of Valneva SE |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 7.41 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 7.41. The average price that VNDA shares were previous bought at was USD 5.46995. The current market price is 35.5% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 5,455 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 32.57 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 32.57. The average price that VRDN shares were previous bought at was USD 30.2601. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in VRDN has increased by USD 82,955 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 21.0277 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 21.0277. The average price that XVIVO.ST shares were previous bought at was SEK 38.3212. The current market price is -45.1% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 4,032 (USD $437) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 23.16 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 23.16. The average price that ZYME shares were previous bought at was USD 19.4668. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in ZYME has fallen by USD 619 compared to the previous valuation of Zymeworks Inc. Common Stock |